Royalty Pharma plcRPRX

Market cap
$16.9B
P/E ratio
14.9x
Dec 31,
2020
Dec 31,
2021
Dec 31,
2022
Dec 31,
2023
Cash collections from financial royalty assets2,1222,3162,5073,201
Cash collections from intangible royalty assets144151731
Other royalty cash collections184470159
Distributions from equity method investees42343919
Interest received832572
Derivative collateral received4535--
Derivative collateral posted-35--
Termination payments on derivative instruments3516--
Development-stage funding payments - ongoing20722
Development-stage funding payments - upfront and milestone619317550
Payments for operating and professional costs180185223243
Interest paid103130170169
Net cash provided by operating activities2,0352,0182,1442,988
Distributions from equity method investees151-44
Investments in equity method investees40351013
Purchases of equity securities5013588-
Proceeds from equity securities385116211-
Purchases of available for sale debt securities-70480-
Proceeds from available for sale debt securities3635421
Purchases of marketable securities1,7051,197235-
Proceeds from Sale and Maturity of Marketable Securities8151,59879224
Acquisitions of financial royalty assets2,1822,1921,7422,116
Acquisitions of other financial assets--21-
Milestone payments-19-12
Net cash used in investing activities-2,759-1,870-1,029-2,073
Other---2
Net cash used in investing activities-2,759-1,870-1,029-2,073
Distributions to shareholders/unitholders285---
Distributions to legacy non-controlling interests - Portfolio Receipts--442377
Distributions to legacy non-controlling interests - Portfolio Receipts--442377
Distributions to legacy non-controlling interests - other18115431-
Distributions to legacy non-controlling interests - other18115431-
Distributions to continuing non-controlling interests544480144120
Distributions to continuing non-controlling interests544480144120
Dividends to shareholders112285333358
Dividends to shareholders112285333358
Repurchases of Class A ordinary shares---305
Contributions from legacy non-controlling interests - R&D8711
Proceeds From Noncontrolling Interests, Other593767
Scheduled repayments of long-term debt94---
Cash acquired in connection with purchase of non-controlling interest---5
Repayments of long-term debt11,116---
Proceeds from revolving credit facility---350
Proceeds from Issuance of Long-Term Debt11,8911,273--
Repayment of revolving credit facility---350
Debt issuance costs and other471312
Repayment of long-term debt---1,000
Proceeds from Issuance Initial Public Offering1,909---
Net (cash used in)/provided by in financing activities1,487385-945-2,149
Debt issuance costs and other471312
Net (cash used in)/provided by in financing activities1,487385-945-2,149
Net change in cash and cash equivalents762532170-1,234